This week, the federal Food and Drug Administration announced its withdrawal of approval for Avastin, a commonly-used breast cancer drug. Avastin, the trade name for the drug bevacizumab, is one of a class of drugs known as “biological therapy.” The drug is a product of Genentech, a biotechnology company based in San Francisco, California. Avastin… Read More